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Abstract
Background: Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for
patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resistance, however,
remain unknown.
Methods: A total of eight cell lines and nine mouse models of breast cancer were treated with entinostat. Luminal
cell lines were treated with or without entinostat at their IC50 doses, and MMTV/Neu luminal mouse tumors were
untreated or treated with entinostat until progression. We investigated these models using their gene expression
profiling by microarray and copy number by arrayCGH. We also utilized the network-based DawnRank algorithm
that integrates DNA and RNA data to identify driver genes of resistance. The impact of candidate drivers was
investigated in The Cancer Genome Atlas and METABRIC breast cancer datasets.
Results: Luminal models displayed enhanced sensitivity to entinostat as compared to basal-like or claudin-low
models. Both in vitro and in vivo luminal models showed significant downregulation of Myc gene signatures
following entinostat treatment. Myc gene signatures became upregulated on tumor progression in vivo and
overexpression of Myc conferred resistance to entinostat in vitro. Further examination of resistance mechanisms
in MMTV/Neu tumors identified a portion of mouse chromosome 4 that had DNA copy number loss and low
gene expression. Within this region, Jun was computationally identified to be a driver gene of resistance. Jun
knockdown in cell lines resulted in upregulation of Myc signatures and made these lines more resistant to
entinostat. Jun-deleted samples, found in 17–23% of luminal patients, had significantly higher Myc signature
scores that predicted worse survival.
Conclusions: Entinostat inhibited luminal breast cancer through Myc signaling, which was upregulated by Jun
DNA loss to promote resistance to entinostat in our models. Jun DNA copy number loss, and/or high MYC
signatures, might represent biomarkers for entinostat responsiveness in luminal breast cancer.
Background
Despite advances in early detection and perioperative
treatments, breast cancer remains the second leading
cause of cancer deaths among women in developed
countries [1]. This is because a certain portion of the
patients continue to develop fatal metastatic disease and
eventually succumb to death. Estrogen receptor (ER)-po-
sitive tumors comprise 70% of the breast cancer popula-
tion and most of them respond to aromatase inhibitors
(AIs); however, others acquire resistance. Currently, the
combinations of CDK4/6 inhibitors, or a mTOR inhibitor
with AIs, have shown improvement of progression-free
survival in patients with metastatic ER-positive breast
cancer [2–4]. Unlike these agents, entinostat, a class I
histone deacetylase (HDAC) inhibitor, may augment re-
sponse to endocrine therapy. HDAC inhibitors have
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been thought to induce histone acetylation leading to
transcriptional re-activation of epigenetically inacti-
vated cancer-associated genes which suppress cell pro-
liferation and promote apoptosis [5]. Class I HDAC
isozymes include HDAC1–3, whose expression has been
shown to be increased in hormone receptor-positive or
high-grade tumors [6]. Indicating the importance of epi-
genetic modification in the context of endocrine therapy,
entinostat with letrozole combination therapy was able to
reduce the volume of letrozole-resistant tumors [7]. From
a safety standpoint, entinostat does not target class II
HDACs which are expressed in the heart [8]; therefore,
this selectivity of entinostat may eliminate serious side ef-
fects such as QT-prolongation and cardiac infarction that
have been associated with pan-HDAC inhibitors [9, 10].
For postmenopausal women with metastatic ER-positive
breast cancer, a randomized phase II trial of entinostat
showed benefits in both progression-free and overall sur-
vival and the incidence of reported cardiac disorders was
similar between entinostat and placebo arms [11]. With
these promising results, entinostat received breakthrough
designation from the Food and Drug Administration
(FDA), and currently, a phase III registration trial E2112
(NCT02115282) is ongoing.
Some HDAC inhibitors, Vorinostat, Panobinostat,
Belinostat, and Romidepsin, have been granted FDA ap-
proval for cancer, yet there are no validated markers for
their clinical decision making. Although c-Myc has been
shown to be a key target for sensitivity to other HDAC
inhibitors in various cancers [12–15], it is still unclear
whether absolute transcriptional or genomic levels of
c-Myc (hereafter, Myc) predict sensitivity to all HDAC
inhibitors. In addition, Myc remains difficult to target
with small molecule Myc inhibitors despite numerous
attempts. As for entinostat in breast cancer, a number of
molecular features have been suggested as underlying
mechanisms of response. This includes upregulation of
ER [7], downregulation of Akt [16], upregulation of
E-cadherin [17], and functional inhibition of myeloid-de-
rived suppressor cells [18, 19]. However, studies detailing
tumor responses to entinostat are still needed to identify
modes of sensitivity and resistance. Here we studied
entinostat’s mechanism of action using multiple models
of luminal and non-luminal breast cancers and identified
two possible biomarkers of resistance.
Methods
Breast cancer cell lines
The human breast cancer cell lines were maintained in
standard growth media (SKBR3, BT474, MCF-7, T47D)
in RPMI (Gibco) plus 10% FBS (Sigma) and anti-biotic
anti-mycotic (Gibco) or in DMEM (Gibco, high glucose)
with 10% FBS (MDA231) [20]. Hs578t and WHIM12 cell
lines were cultured in HuMEC media with supplements
(Gibco) plus Bovine Pituitary Extract (Gibco) and anti-
biotic anti-mycotic (Gibco). WHIM12 is a patient-de-
rived xenograft cell line obtained from Matthew Ellis
(Baylor College of Medicine). All cell lines were grown
at 37 °C and 5% carbon dioxide and were obtained from
the American Type Culture Collection unless otherwise
specified.
Cell proliferation assay
The effects of entinostat on the proliferation of vari-
ous human or mouse cancer cell lines were deter-
mined by using the [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetra-
zolium [21] assay (CellTiter 96® AQueous One Solution
Cell Proliferation Assay, Promega), except for T47D where
the effects were measured using Cell titer glo (Promega).
A total of 3000–5000 cells were seeded into 96-well cul-
ture plates and treated with entinostat (Sigma) for 72 h
and then treated with MTS for 2 h. Cell viability was
determined by measuring the absorbance at 490 nm. Six
replicates for each time point were measured. The gener-
ation of dose-response curves was performed using the
GraphPad Prism.
Genetically engineered mouse models (GEMMs)
GEMMs of strain FVB carrying a transgene for rat HER2
(MMTV/Neu) [22] and C3 SV40 T-antigen (C3tag) [23], or
patient-derived xenografts (PDXs) WHIM8 and WHIM35
[24] in Nod-Skid-Gamma (NSG) mice were bred in-house
and observed until the onset of a mammary tumor approxi-
mately 0.6 cm in any dimension. Tumors derived from
TP53 −/− mammary gland transplant lines (T2, T11,
2225L, 2208L, and 2396R) [25] were passaged in BALB/c
wild-type mice by subcutaneous injection of one half mil-
lion cells resuspended in Matrigel into the mammary fat
pad as previously described [26]. A minimum tumor vol-
ume of approximately 0.6 cm in size was used as the start-
ing point for treatment studies; 12–28 mice for each
experiment were randomized into untreated or treated
groups and monitored with tumor growth measurements
(Additional file 1: Figure S1). For C3tag and MMTV/Neu
mice, we added information on 30 or more mice using his-
torical controls, as well as contemporaneous controls.
Tumor volumes were measured by caliper as (width) × (
length)2/2 for MMTV/Neu or C3tag and π/6 × (length)3 for
transplant lines. Entinostat (Sigma) was milled into chow at
12mg/kg, which was determined by in-house dose-finding
study of entinostat. For short-term response, tumor size
was measured at baseline for all the models and at 7-day
point for 2225L, 10-day point for 2396R and T2, 14-day
point for 2208L, and 21-day point for WHIM8, WHIM35,
T11, C3tag, and MMTV/Neu. Treatment periods were
dependent on inherent tumor line growth rates, and the per-
cent change in volume was used to quantify response. For
Tanioka et al. Genome Medicine           (2018) 10:86 Page 2 of 14
survival, treatment with entinostat was started at time
zero (i.e., tumor 0.6 cm) and continued until either the
mouse developed a tumor burden sufficient to warrant
euthanasia (2 cm in any dimension) or until weight loss
totaling 20% of the initial starting body mass was ob-
served. All work was done under protocols approved by
the University of North Carolina (UNC, Chapel Hill,
NC) Institutional Animal Care and Use Committee.
DNA, RNA, and protein extraction
Total RNA was purified using the RNeasy Mini kit
(Qiagen), and DNA was extracted using the DNeasy Kit
(Qiagen). We extracted nuclear protein using NE-PER
nuclear and cytoplasmic extraction reagents (Thermo
Scientific). Following extraction, protein concentration
was determined using Micro BCA protein assay kit
(Thermo Scientific).
Gene expression and signature analysis
A total of 1 μg human RNA or 2 μg of mouse RNA were
purified and profiled as described previously using DNA
oligo microarrays (Agilent Technologies, USA) [27]. The
LOWESS normalized log2 ratios (Cy5 sample/Cy3 con-
trol) of probes mapping to the same gene (Entrez ID)
were averaged to generate gene-level expression estimates.
Gene expression changes were measured in luminal cell
lines SKBR3 (ER-/HER2+), BT474 (ER+/HER2+), and
MCF7 (ER+/HER2-) treated with or without entinostat at
their IC50 doses. Significantly differentially expressed
genes were identified (false discovery rate of 0%) using
unpaired two-class significance analysis of microarrays
(SAM) [28] to compare untreated vs. entinostat-treated
samples. Hierarchical clustering using 814 of The Gen-
ome Cancer Atlas [29] breast cancer samples was done
using Gene Cluster 3.0 [30]. For hierarchical clustering
analyses, the genes/rows were median centered, and
clustering of arrays was conducted with correlation
centered genes and arrays, and centroid linkage. Array
cluster viewing and display were conducted using Java-
Treeview v1.1. 5r2 [31]. We defined “signatures” as any
gene set that contained a minimum of 10 genes and a
Pearson node correlation greater than 0.5 in this TCGA
breast cancer hierarchical cluster dataset.
We investigated the significance of gene signatures
using the “Investigate Gene Sets” method of Gene Set
Enrichment Analysis (GSEA, http://software.broadinstitute.
org/gsea/msigdb/annotate.jsp) [32]. We also applied a col-
lection of 517 publicly available, gene expression signatures,
representing multiple biological pathways and cell types as
well as entinostat signatures [33]. These 517 signatures
have all been published [34] and obtained from 73 publica-
tions or GSEA [32] and partially summarized by Fan et al.
[35]. Using the TCGA data, we applied each signature to
the dataset in a manner consistent with their derivation.
For 480 signatures with homogeneous expression across
genes, we used the median expression value from all genes
within a signature, and 37 signatures were based on correl-
ation to predetermined gene centroids or based on
pre-specified published algorithms.
Using the gene expression data from SKBR3, BT474,
and MCF-7 treated with or without entinostat, we also
investigated three Myc gene signatures which represents
Myc signaling: MYC.1PFDR_UP [21] and MYC.2012
[36] derived from breast cancer mouse models comparing
MMTV-Myc and other models, and DUKE.MODULE13
[37] comparing Myc-overexpressed versus control human
mammary epithelial cells. Genes in mouse and human
version of signatures are shown in Additional file 2:
Table S1. We used the median expression value from
all genes in each signature as a gene signature score.
In addition, a total of 27 MMTV-Neu mouse tumors
(luminal subtype) were untreated (N = 8) or treated with
entinostat at 12mg/kg for 3 weeks (N = 5), 6 weeks (N = 6),
or until progression after complete response (N = 8). We
profiled gene expression of these tumors and calculated
MYC gene signature scores for each subgroup. Using the
Mouse Genome Database (http://www.informatics.jax.org/
homology.shtml), the lists of human MYC gene signatures
were converted to orthologous mouse genes.
Lentiviral transfection
To determine whether Myc or Jun levels influence the
effects of entinostat on cell viability, we transfected lu-
minal breast cancer cells with lentiviruses expressing the
non-degradable, phosphorylation mutant (T58A) of Myc
or two kinds of shRNA targeting Jun. To overexpress
MycT58A or mCherry, constructs in pLEX-MCS-puro
vector (Thermo Scientific) were kindly provided by Gary
L Johnson [9]. HEK293T cells were transfected with Li-
pofectamine 2000 (Invitrogen) with pLEX-MCS-puro
constructs and packaging plasmids. Forty-eight hours
after transfection, viral supernatant was collected and fil-
tered through 0.45-μm syringe filters. To knockdown Jun
expression, shRNA for Jun and scramble DNA as a con-
trol were obtained from Cyagen and the pLV-Puro-U6
vector was used. Target sequences for Jun knockdown
were ATTCGATCTCATTCAGTATTA or TTCTGGCCT
GCCTTCGTTAAC at 3′UTR of Jun (i.e., two different
RNAi targeting constructs). After SKBR-3 or MCF-7 cells
were transduced with lentivirus-mediated mutant Myc
with in the presence of 6 μg/ml polybrene, the cells were
incubated in various doses of entinostat for 72 h, and then
the viability of cells was measured using the MTS assay.
Likewise, BT474 or T47D cells were transfected with
lentivirus-mediated shRNA for Jun.
Expression levels of Myc or Jun protein in nucleus
were determined by Western blot following recommen-
dations of antibody suppliers. Antibodies used were
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HA-tag for exogenous Myc (C29F4, Cell Signaling), en-
dogenous Myc (D3N8F, Cell Signaling), Jun (60A8, Cell
Signaling), and beta-actin (#4967, Cell Signaling) as a
housekeeping gene. The relative chemiluminescent in-
tensities were quantified in individual frames using
ImageJ software (NIH).
Assessment of DNA copy number changes in MMTV/Neu
tumors
To investigate DNA copy number changes, we used the
custom HD-array Comparative Genomic Hybridization
(aCGH) platform which was designed and built on the
Mouse 244 k Custom Oligo platform (GPL15359 Agilent
UNC Perou Lab 1 × 244 k Custom Tiling CGH Array).
Two hundred thirty thousand six hundred and six
probes cover a total region of 45Mb, and this design
gives an average resolution of 200 bp between contigu-
ous probes. Labeling and hybridization were performed
according to the manufacturer’s instructions using the
Agilent Genomic DNA Labeling Kit PLUS (Catalog
Number 5188–5309). One microgram of DNA from liver
or spleen of FVB strain mouse was used as normal refer-
ence DNA, which was compared versus 1 μg of DNA from
every mouse tumor sample. Microarrays were scanned on
an Agilent DNA Microarray scanner (G2565CA) and the
data uploaded to the University of North Carolina Micro-
array Database (www.genome.unc.edu). To determine re-
gions of Copy Number Aberration (CNA), we utilized the
R package SWITCHdna [38], which can identify break-
points in aCGH data. SWITCHdna detects transition
points that maximize the F statistic and have regions on ei-
ther side of the breakpoint that are larger than 250 kb. Fol-
lowing detection of the transition points, a log2-ratio
segment average value and corresponding z-score are deter-
mined, along with the number of observations used. In this
study, we used a z-score of 3 and a minimum intensity
measurement of 0.09. The end results are the identification
of segments of CNA, along with a quantitative value for
that copy number change (i.e., loss or gain). All subsequent
plots were produced after applying this significance filter to
our data. These segment-level copy number values were
changed into gene level using R package Switchplus [39].
DawnRank analysis
We used the DawnRank algorithm [40] as a novel compu-
tational method that uses within-tumor integrated ana-
lyses of DNA aberrations in context of RNA expression
that is used to population predetermined protein-protein
networks in order to find possible individual driver genes
that might predict resistance to entinostat. Using the
DawnRank predefined protein-protein interaction net-
works, we populated this network with mRNA gene ex-
pression data for each sample and calculated a score for
each gene based upon expression of the genes connected
to it in the network. Using somatically altered genes with
CNA data described above, we applied DawnRank to four
groups of the MMTV-Neu mouse tumors which were un-
treated (N = 6), or treated with entinostat at 12mg/kg for
3 weeks (N = 4), 6 weeks (N = 4), or until progression after
complete response (N = 8) according to the “percentrank”
analysis mode, which aggregates the DawnRank results
across a predefined set of samples.
TCGA and METABRIC samples
Two independent publicly available human breast cancer
datasets, TCGA [29] and METABRIC [41], were investi-
gated to validate the impact of Jun deletion. We used
PAM50 intrinsic subtypes, mRNA expression, and DNA
copy number changes in 814 primary breast tumors
from TCGA. PAM50 intrinsic subtypes and mRNA ex-
pression data are publicly available at cBioPortal website
(http://cancergenome.nih.gov/). Copy number variation
across the genome was determined as follows: The se-
quence reads were aligned to the genome (hg 19) using the
bwa mem algorithm (https://github.com/lh3/bwa; v0.7.4)
with the default parameters. Duplicates were removed using
Picard (http://broadinstitute.github.io/picard/). Quality sta-
tistics were also generated with Picard including measures
of fragment length, sequence content, alignment, capture
bias and efficiency, coverage, and variant call metrics. Copy
number assessments were performed using SynthEx [42].
In brief, counts data for fixed 100-kb bin were generated
using BEDTools [43]. The read ratios were calculated using
the “synthetic normal” strategy described in SynthEx. A
trending filter procedure was applied to segment the gen-
ome. The segment-level copy number values, which is the
log2 ratios of normalized signal intensities between tumor
and reference, were finally corrected by purity and ploidy
estimates from SynthEx, taking whole genome doubling
into account for these values. These segment-level values
were changed into gene-level using Switchplus [39]. Copy
number values derived from exome sequencing were com-
pared with those from SNP6.0 among the TCGA samples
[44] with ploidy 1.75–2.5, then the thresholds for gain or
loss were determined as 0.25 or − 0.32, respectively [42]; we
applied these thresholds to copy number values on the
TCGA samples to call gained and lost segments. All
genomic data, including DNA copy number and gene
expression, have been deposited into the GEO (series
ID GSE118744).
The METABRIC human breast cancer dataset includes
breast cancer-specific survival data as well as gene ex-
pression and DNA copy number data of 1992 resected
primary breast tumors. All clinical and genomic data are
also publicly available at the cBioPortal. Copy number
datasets within the portal are generated by GISTIC [45]
to determine the copy number status of each gene in
each sample. Amplification or deletion was determined
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by applying both low- (− 1, − 2) and high-level (+ 1, + 2)
thresholds to the gene copy levels of all the samples. In
our study, Jun copy number loss was defined by “− 2”
(possibly a homozygous deletion) and “− 1” (possibly a
heterozygous deletion). To investigate the clinical impact
of three Myc signatures (Myc_1pFDR, Myc.2012, or
Duke_Module13_myc), the patients with luminal A or
luminal B PAM50 subtype [46] breast cancers were clas-
sified into three rank order groups according to scores
from each Myc signature. To investigate clinical impact
of Jun copy number loss, the patients were classified into
groups with/without Jun copy number loss, and breast
cancer-specific survival was assessed by Kaplan-Meier
curves. Patients with survival of > 20 years were excluded.
Two-sided log-rank tests and univariate Cox regression
analyses were conducted to determine significance of each
endpoint.
Statistical analyses on signature scores, box plots,
SAM, DawnRank, and Kaplan-Meier curves of human
samples were performed using R version 3.1.2, while
generation of survival curves or response plots on mouse
models, and IC50 curves on cell lines were performed
using the GraphPad Prism version 7 software (GraphPad
Software, San Diego).
Results
Sensitivity to entinostat among breast cancer models in
vivo and in vitro
Given the promising phase II results for entinostat, our
study sought to clarify the mechanism(s) of entinostat
sensitivity and to find biomarker(s) to predict its sensi-
tivity or resistance in human breast cancer. As a first
step, we investigated preclinical models of breast cancer
for entinostat sensitivity. To examine sensitivity in vitro,
we identified the IC50 doses of entinostat for seven hu-
man breast cancer cell lines (Fig. 1a). Cell lines with lu-
minal features (BT474, MCF-7, SKBR3, and T47D) were
more sensitive to entinostat compared with basal-like or
claudin-low (MDA231, Hs578t, and WHIM12) cell lines.
Luminal model sensitivity was confirmed in vivo by test-
ing murine luminal, basal-like, claudin-low TP53−/−
GEMMs, and PDX models, with entinostat at 12 mg/kg
(Fig. 1b). Entinostat generally inhibited tumor growth
for most murine models, irrespective of subtype, but
only the luminal MMTV/Neu murine tumors presented
a complete reduction in tumor volume after treatment
of entinostat. In addition, we assessed the effects of enti-
nostat on the overall survival of tumor-bearing mice. Al-
though entinostat generally prolonged the survival for
mice with any of the tumor types, entinostat greatly ex-
tended lifespan from a median of 29 to 123 days in
MMTV/Neu (Additional file 1: Figure S1). Figure 1d
shows a time course of eight MMTV/Neu tumors from
six mice; although they initially responded to entinostat
completely, recurrent tumors emerged after the 5–10
weeks of entinostat treatment. In addition, we note some
tumors (180226-Lt.Neck and 180,165-Lt.inguinal tu-
mors) appeared after a long latency, perhaps suggesting
initial repression of tumorigenic cells that emerged with
acquired resistance.
Global gene expression change caused by entinostat in
luminal breast cancer
To identify signatures of entinostat-regulated genes,
gene expression analyses were performed. Luminal cell
lines SKBR3 (ER-/HER2+), BT474 (ER+/HER2+), and
MCF7 (ER+/HER2-) were treated with or without enti-
nostat at their IC50 doses for 72 h and their gene expres-
sion profiles determined. Differential expression analysis
between untreated vs entinostat-treated cell lines re-
vealed 563 upregulated and 565 downregulated genes
with FDR of 0% (Additional file 2: Table S2-A). We hier-
archically clustered these two gene lists using 817 TCGA
breast cancer samples, then defined “signatures” as any
gene set that contained a minimum of 10 genes and a
Pearson node correlation of greater than 0.5. Using
these criteria, we defined six upregulated signatures
and three downregulated signatures (Fig. 2a, all genes
in signatures listed on Additional file 2: Table S2-B).
We next investigated the potential impact of each sig-
nature on the survival among luminal breast cancer
samples in METABRIC (Additional file 1: Figure S2-A).
In addition, we plotted the scores for each entinostat
signature according to PAM50 intrinsic subtypes using
TCGA breast tumors (Additional file 1: Figure S2-B).
Figure 2b shows the summary of the characteristics of
all signatures. Within the downregulated gene signa-
tures, down signature 1 (285 genes) had significant cor-
relations with HALLMARK_MYC_TARGETS_v1 (q-value,
2.7e− 17) and HALLMARK_MYC_TARGETS_v2 (q-value,
1.7e− 4) in the GSEA “Investigate gene set” analysis. Simi-
larly, when TCGA samples were scored for these entinostat
signatures with 517 other signatures, clustering analysis
revealed the down signature 1 was correlated with
three Myc signatures (MYC.1PFDR_UP, MYC.2012, and
DUKE.MODULE13) as well as many proliferation sig-
natures (Pearson correlation, 0.64).
Entinostat inhibits luminal breast cancer through Myc
signaling
Figure 3a illustrates that Myc signature scores goes
down after treatment with entinostat at their IC50 doses
in three luminal human cell lines. Myc is well appreci-
ated as an oncogene that has been shown to induce
HDAC2 (a major target of entinostat) in colorectal [47]
and pancreatic cancer [12]; therefore, we sought to ex-
perimentally validate the role of Myc signaling in sensi-
tivity to entinostat. Using lentiviral transfection of Myc
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or a phosphorylation incompetent mutant MycT58A, we
tested the impact of Myc overexpression on entinostat
sensitivity. Western blot analysis confirmed Myc over-
expression, and quantification revealed that protein
levels of Myc were 3.2- and 16.5-fold higher than con-
trol cells in SKBR3 and ZR75-1, respectively. Similarly,
MycT58A overexpressed cells had 5.4-, 1.4-, and 5.4-fold
higher Myc protein levels than control cells in SKBR3,
MCF7, and ZR75-1, respectively (Additional file 1: Fig-
ure S3-A & S3-C). Importantly, we observed that Myc
and MycT58A overexpression in SKBR3, MCF-7, and
ZR75-1 cells increased resistance to entinostat (Fig. 3b–d).
Examining gene expression profiles of MMTV/Neu tu-
mors responding to entinostat at a 3-week time point con-
firmed a reduction in expression of Myc and Myc target
genes. Myc signature scores stayed in a low level at the
6-week point but increased when the tumors became
resistant to entinostat (Fig. 3e, the changes in tumor
size are shown in Additional file 2: Table S3). Further,
Myc gene signatures did not change between 16 un-
treated vs 5 treated C3tag tumors, which did not re-
spond to entinostat for 3 weeks (p = 0.99, data not
shown). Taken together, these results demonstrate Myc
as a possible target of entinostat therapy and point to
Fig. 1 Luminal breast cancer is sensitive to entinostat in vivo and in vitro. a Antiproliferative activities of entinostat in breast cancer cells. The
effects of entinostat on the proliferation of various human or mouse cancer cell lines were determined by using the [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium [21] assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega).
Cells were seeded into 96-well culture plates and treated with entinostat for 3 days, and then treated with MTS for 2 h. Cell viability was determined by
measuring the absorbance at 490 nm. Inhibitory concentration (IC) curves are shown with IC50 values in legend. b Short-term treatment responses for
seven mouse models of mammary cancer. The models used were p53 null T2 and T11 which were chosen based on their similarity in gene expression
to claudin-low subtype, 2396R, 2225L, and C3tag whose subtype was basal-like, WHIM8 and WHIM35 whose subtypes were HER2-enriched [24], and
2208L and MMTV/Neu whose subtypes were luminal [25]. Entinostat at 12mg/kg was continuously administered via the chow. Tumor size was
measured at baseline for all the models and at 7-day point for 2225L, 10-day point for 2396R and T2, 14-day point for 2208L, and 21-day point for T11,
WHIM8, WHIM35, C3tag, and MMTV/Neu. Treatment periods were dependent on their faster growth rate. The change in tumor volume is plotted as
whisker plots shown as measures of tumor responsiveness for entinostat-treated models with their matched untreated control. The error bars
represent the 95% CIs. The number of animals in each treatment group is indicated in parentheses. Mann-Whitney tests were conducted
between untreated control and entinostat-treated group for each mouse model. *, < 0.05; **, < 0.01; ***, < 0.001; ns, not significant. c A total
of eight MMTV/Neu tumors from six mice showed complete response but finally became resistant to entinostat chow (12mg/kg). 180226-Lt.Neck or
180165-Lt.inguinal were not detected at the beginning but appeared after 63 or 77 days of treatment, respectively
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repression of Myc target genes as a critical mediator of
sensitivity.
Genomic Jun loss causes resistance to entinostat
To identify potential mechanisms of resistance, we ana-
lyzed MMTV/Neu sensitive and resistant tumors by
aCGH (Fig. 4a). Copy number aberration in untreated
tumors was few. However, a large portion of mouse
chromosome 4 showed DNA copy number loss in tu-
mors that progressed while on entinostat for a long time.
This observation led us to hypothesize that copy number
loss at Chr.4 conferred resistance to entinostat. To test
for driver genes responsible for the resistance, we used
DawnRank analysis [40] to integrate copy number data
with the gene expression data from MMTV/Neu tumors
that were untreated, treated for 3 weeks, treated for 6
weeks, or treated until progression. Table 1 shows the
DawnRank results where the top-ranked genes with copy
number aberration are listed among MMTV/Neu tu-
mors treated with entinostat. Jun was computationally
identified to be a top driver gene with copy number loss
associated with resistance/progression. Not only the
ranking but also the percent rank of Jun gene increased
from 0.977 at 3-week point (which means top 2.3% in
the network) to 0.999 (top 0.1%) at the time of progres-
sion. We detected 83 genes, including Jun, at Chr.4,
which significantly decreased their gene expression and
DNA copy number levels with q-value 0% by supervised
analysis comparing the untreated samples with the
samples that became resistant while on entinostat
(Additional file 2: Table S4). Of note, the entirety of
samples resistant to entinostat showed significantly
lower copy number in a region at Chr.4 between
80,385,673 and 101,147,931, where Jun is located. In
addition, we note a reduction of Jun gene expression
levels with the duration of entinostat therapy (Fig. 4b).
To test the hypothesis that Jun copy number loss
causes resistance to entinostat, we sought to determine
whether Jun levels influence the effects of entinostat on
cell viability. Lentiviral transfection of Jun shRNA re-
duced Jun protein expression levels by 54–70% in
BT474 and T47D (Additional file 1: Figure S3-B & S3-C).
In support of our hypothesis, reduction of Jun by shRNA
imparted BT474 and T47D cells with increased resistance
to entinostat (Fig. 4c, d).
Genomic Jun copy number loss correlates Myc signaling
activity
Given that sensitivity to entinostat was dependent on re-
pression of Myc target genes and that resistance to enti-
nostat was marked by Jun loss, we examined whether
loss of c-Jun restored the molecular features of Myc acti-
vation. Suggesting coordination between Myc and c-Jun,
we noted that Myc mRNA or signature levels increased
as Jun copy number loss became deeper in MMTV/Neu
samples while treated with entinostat (Fig. 3e and
Fig. 4a). Therefore, we investigated the relationship be-
tween Jun copy number loss and Myc signaling in the
luminal cell line BT474. Jun knockdown in BT474 corre-
lated with upregulation of Myc gene or signature scores
(Fig. 5a). To test whether our observations in preclinical
models might extend to human breast cancer patients,
we examined Jun copy number in human breast cancer
datasets. Jun-deleted human tumors had significantly
higher levels of Myc gene or signatures among both
TCGA and METABRIC luminal breast cancer samples
(Fig. 5b, c). All three Myc signatures were prognostic
Fig. 2 Entinostat inhibits luminal breast cancer through Myc signaling.
a 563 upregulated and 565 downregulated genes with false positive
rate (FDR) of 0% were hierarchically clustered using 817 TCGA breast
cancer samples. We defined “signatures” as any gene set that contained
a minimum of 10 genes and a Pearson node correlation greater than
0.5 in TCGA dataset. Using these criteria, we defined six and three
signatures in upregulated and downregulated genes, respectively.
b The summary of the characteristics of all signatures
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among luminal breast cancer samples in METABRIC as
well (Fig. 5d–f ), and multivariable analyses accounting
for age, tumor size, nodal status, and HER2 status
showed two out of three Myc signatures were still
significantly prognostic (Additional file 2: Table S5). Col-
lectively, these results suggest that genomic DNA Jun
copy number loss allows activation of Myc signaling,
which in turn promotes resistance to entinostat therapy.
Fig. 3 Myc signaling controls entinostat sensitivity. a Myc signature analysis of entinostat-treated human breast cancer cell lines. Box and whisker
plots for the Myc gene signatures (Myc.sig.1PFDR_UP, Myc.sig.2012, or Myc.sig.DUKE) using the data from SKBR3, BT474, and MCF-7 treated with
or without entinostat at their IC50 doses for 72 h. Each colored square represents the relative median transcript abundance (in log2 space) of each
signature for untreated SKBR3, BT474, MCF-7 being light blue, blue or light green, or entinostat-treated SKBR3, BT474, MCF-7 being green, pink, or
red. b–d Sensitivity to entinostat in luminal breast cancer cell lines with lentiviral Myc constitutive overexpression. After SKBR-3 (b), MCF-7 (c), or
ZR75–1 (d) cells were transfected with lentivirus-mediated Myc shRNA, the cells were incubated in various doses of entinostat for 72 h, and then
the viability of cells was measured using the MTS assay. Inhibitory concentration (IC) curves are shown with IC50 values in legend. Each point
represents the mean ± standard deviation of sextuple determinations. Myc shRNA treatment makes luminal breast cancer cells more resistant
toward entinostat as evidenced by an increase in IC50. e Myc gene expression (Myc_gene) or Myc signatures (Sig.1PFDR_UP, Sig.2012, Sig.Duke) in
27 MMTV/Neu luminal mouse model tumors untreated (N = 8) or treated with entinostat at 12 mg/kg for 3 weeks (N = 6), 6 weeks (N = 5), or until
progression (N = 8)
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Fig. 4 Jun copy number loss causes resistance to entinostat. a Copy number landscape of entinostat-treated MMTV/Neu tumors by arrayCGH.
aCGH analysis revealed that a large portion of mouse Chromosome 4 had DNA copy number loss in tumors that progressed while on entinostat.
Segments of copy number gains are plotted above the x-axis in red and loss are plotted below the x-axis in green. The frequency of alterations is
indicated on the y-axis from 0 to 100%. b Jun gene expression in 27 MMTV/Neu luminal mouse model tumors untreated (N = 6) or treated with
entinostat at 12 mg/kg for 3 weeks (N = 6), 6 weeks (N = 5), or until progression (N = 8). Each square represents the relative median transcript
abundance (in log2 space) of each signature for untreated or entinostat-treated MMTV/Neu. c, d Sensitivity to entinostat in BT474 or T47D with
lentiviral c-Jun knockdown. Jun shRNA treatment makes BT474 or T47D cells resistant toward entinostat as evidenced by an increase in IC50. After
BT474 or T47D cells were transfected with lentivirus-mediated Jun shRNA, the cells were incubated in various doses of entinostat for 72 h and
then the viability of cells was measured using the MTS assay. Each point represents the mean ± standard deviation of sextuple determinations.
Inhibitory concentration (IC) curves are shown with IC50 values in legend
Table 1 DawnRank analysis of entinostat-treated MMTV/Neu samples
Untreated (N = 6) Entinostat-3wks (N = 4) Entinostat-6wks (N = 4) Entinostat-resistant (N = 8)
Gene Percent rank Chr Gene Percent rank Chr Gene Percent rank Chr Gene Percent rank Chr
MAX 1 12 JUN 0.977 4 JUN 0.997 4 JUN 0.999 4
CALM1 0.995 12 CDC42 0.975 4 CDC42 0.994 4 JAK1 0.995 4
HIF1A 0.990 12 JAK1 0.969 4 JAK1 0.992 4 CDC42 0.990 4
ACTN1 0.986 12 LCK 0.969 4 LCK 0.989 4 CDKN2A 0.989 4
FOS 0.981 12 LYN 0.965 4 LYN 0.987 4 LCK 0.987 4
HSP90AA1 0.976 12 MAP3K7 0.960 4 MAP3K7 0.984 4 TGFBR1 0.984 4
FOXA1 0.972 12 ERBB2 0.959 11 CDKN2A 0.982 4 LRP8 0.983 4
ARF6 0.967 12 CDKN2A 0.952 4 ZBTB17 0.979 4 ZBTB17 0.981 4
FBLN5 0.963 12 TGFBR1 0.950 4 TGFBR1 0.977 4 TLE1 0.980 4
NCOA1 0.958 12 RBBP4 0.948 4 RBBP4 0.974 4 LYN 0.980 4
NFKBIA 0.953 12 ZBTB17 0.944 4 LRP8 0.972 4 RBBP4 0.979 4
Chr, mouse chromosome; Entinostat-3wks, Entinostat-6wks, Entinostat-resistant are samples treated with entinostat for 3weeks, 6weeks, and until progression, respectively
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Clinical impact of Jun copy number loss in human breast
cancer datasets
Jun DNA copy number values are generally lower in pa-
tients with luminal A and luminal B breast cancers
(Fig. 6a). The frequencies of Jun copy number loss in lu-
minal breast cancer were 23% and 17% in TCGA and
METABRIC, respectively (Fig. 6b). Patients with Jun
copy number loss had a worse prognosis among luminal
breast cancer samples in METABRIC (Fig. 6c). Further,
patients with Jun copy number loss who received hor-
monal therapies also had worse prognosis compared
with similar patients without Jun copy number loss
Fig. 5 Genomic Jun copy number loss correlates Myc signaling activity. a Box and whisker plots are shown as Myc gene expression (Myc.gene) or
signature (1PFDR_UP, 2012, DUKE) scores in BT474 with lentiviral c-Jun or scramble shRNA (Control). The middle bar in each square represents
standardized, average values. The square represents the interquartile range (25th and 75th percentiles). b Myc gene expression or signature scores
in luminal TCGA breast cancer samples with Jun deletion (N = 136) or without Jun deletion (amplified/normal, N = 452). c Myc gene expression
or signature scores in luminal METABRIC breast cancer samples Jun deletion (N = 204) or without Jun deletion (amplified/normal, N = 1002).
d–f Kaplan-Meier plots on breast cancer-specific survival in 1091 luminal breast cancer patients in METABRIC. Patients with survival of > 20
years were excluded. Patients were classified into three groups with lower, middle, or top third of the scores derived from the Myc signature
scores using Myc_1pFDR (d), Myc.2012 (e), or Duke_Module13_myc (f). Two-sided log-rank tests and univariate Cox regression analyses were
conducted to determine significance of each Myc signature
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(Fig. 6d). We additionally performed survival analysis ac-
cording to Jun copy number status and each Myc signa-
ture among METABRIC patients with luminal breast
cancer who received hormonal therapies (Additional file 1:
Figure S4). Patients with Jun-deleted/high Myc signature
score had the worst prognosis (light green line), while pa-
tients with Jun-non-deleted/low Myc signature scores had
the best prognosis (pink line). These results suggest that
Jun copy number loss is frequently observed in human
breast cancer patients, is prognostic of worse outcomes,
and might be a genetic cause of resistance to entinostat
among patients with luminal tumors who receive hormo-
nal therapies.
Discussion
With our work, we identify a complex interplay between
the HDAC inhibitor entinostat, c-Jun, and Myc. Preclin-
ical models, both human and murine, of luminal sub-
types exhibited sensitivity to entinostat compared to
basal-like or claudin-low subtypes. Importantly, we show
that entinostat inhibited luminal breast cancer through
Myc signaling, and genomic Jun loss upregulated Myc
signaling to promote resistance to entinostat. Our find-
ings indicate that Jun copy number loss might, therefore,
represent a useful biomarker for entinostat resistance in
luminal breast cancer where these Jun-deleted patients
might be suggested to not receive entinostat containing
regimens. Another alternative biomarker for entinostat
resistance could also be high Myc signature expression.
These novel findings are to the best of our knowledge,
have not been previously reported.
Myc is the most frequently amplified oncogene [48]
and it is known to regulate transcription of genes in-
volved in cell growth and proliferation [49, 50]. The
functions of Myc is influenced by multiple mechanisms
in tumor cells: protein ubiquitination, gene amplifica-
tion, chromosomal translocation, mutation, co-factor ex-
pression, and mutation of upstream signaling pathways
[51–55]. Therefore, transcriptional or genomic levels of
Myc itself do not always reflect on its activity. Gene sig-
natures of Myc target genes might better reflect on Myc
activity; however, Myc amplifies thousands of actively tran-
scribed genes within each cell type, so every cancer has a
different, specific cohort of Myc target genes [56, 57]. This
is the reason why we investigated a number of different
Myc signatures, all of whom were derived from breast epi-
thelial tissues, and all were prognostic in patients with lu-
minal breast cancer (Fig. 6). In our study, Myc signatures
were repressed while breast epithelial cells were responsive
on entinostat, and Myc signatures were reactivated upon
Fig. 6 Clinical impact of Jun copy number loss in human breast cancer datasets. a Log2-based value of Jun copy number across the intrinsic
subtypes in 814 TCGA breast cancer patients. Whiskers represent the 5%–95% distribution, boxes represent the interquartile range (25th and 75th
percentiles), and the horizontal line in the box represents the median value. Cut-off value of Jun copy number for deletion was − 0.32. ANOVA p
value was calculated by comparing Jun copy number values across all subtypes. b Frequencies of samples with Jun deletion in TCGA (n = 814) or
METABRIC (n = 1960) according to the intrinsic subtype. c, d Kaplan-Meier plots on breast cancer-specific survival among luminal breast cancer
patients in METABRIC. Patients with survival time of > 20 years were excluded. c Whole luminal A and B breast cancer patients (N = 1091). Cox p
value = 8.12e−06. d Luminal breast cancer patients who received hormonal therapies (N = 830). Cox p value = 0.033
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progression in vivo. Myc signatures were repressed
after entinostat treatment at IC50 doses and Myc over-
expression resulted in resistance to entinostat in vitro.
These data support the hypothesis that Myc represents
an important modulator for response to entinostat as
extensive evidence on other HDAC inhibitors has sug-
gested [12–15].
This study also revealed that a specific region of
mouse chromosome 4 was recurrently deleted in every
entinostat-resistant MMTV/Neu tumor obtained (n = 8),
but not in untreated tumors. This deletion has been re-
ported in a variety of luminal breast cancer mouse
models like MMTV/Neu and p53 null luminal tumors
[25, 39, 58, 59]. Major human counterparts of mouse
chromosome 4 are Chr.1p31-36 and Chr.9; loss of het-
erozygosity on 1p (where c-Jun is) occurred preferen-
tially in a subclass of estrogen receptor-positive breast
cancers [60] and has been shown as a poor prognostic
factor [61–63]. These findings imply that deleted mouse
chromosome 4 drives tumor aggressiveness, and this is a
region also linked to poor outcomes in human luminal
breast cancers as well.
To identify possible drivers in this luminal tumor con-
served region of deletion, we used a network-based, inte-
grated bioinformatics analysis (i.e., DawnRank) that
identified Jun deletion at mouse chromosome 4 as the
top driver gene upon progression during entinostat
treatment. Knockdown of Jun expression in luminal cells
increased resistance to entinostat (Fig. 4c, d), and gen-
omic loss of Jun at 1p32, which was found in 17–23% of
patients with luminal breast cancer, was significantly
prognostic among patients with luminal breast cancer
who received anti-hormonal therapies (Fig. 6). Further-
more, we found Jun-deleted samples had higher Myc sig-
nature scores in vitro and in vivo in human breast
cancer (Fig. 5). Similar findings have been found be-
tween loss of heterozygosity of chromosome 1p32-pter
and amplification of Myc [64]. The precise molecular
mechanism(s) as to how Jun deletion causes upregula-
tion of Myc signaling remains unclear, but the inter-
play between Jun and Myc has been previously
reported [65, 66]. In detail, Jun/Ap-1 complex might
regulate Myc directly [65] or Jun loss may modulate
Myc function indirectly [66]. We would propose a
mechanism that genomic Jun loss constitutively acti-
vates Myc signaling, which leads to poor outcomes in
general, and possible resistance to entinostat. Measuring
Jun DNA copy number loss is one of the candidate bio-
markers for a clinical test, if entinostat achieves approval.
Alternatively, gene expression of Myc signatures are also a
clinical test candidate; those who have high Myc signature
would be predicted to have resistance to entinostat. Lastly,
we will need retrospective analysis of existing clinical trials
to determine which one is the best.
Conclusions
Entinostat inhibited luminal breast cancer through Myc
signaling, which was upregulated by Jun DNA loss to
promote resistance to entinostat in our models. Here we
also provide a testing platform using MMTV/Neu with
genomic Jun loss for combination therapies with entino-
stat to provide more durable response to Jun-deleted hu-
man luminal breast cancer. Further studies will be
certainly required to validate the significance of genomic
Jun loss in prospectively collected luminal breast cancer
samples under treatment of entinostat.
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